NIH HIV TWIN GENE THERAPY STUDY APPROVED BY RAC; TOTAL OF FIVE PROTOCOLS RECEIVE OKAY FROM RAC, INCLUDING FIRST FOR CHRONIC GRANULOMATOUS DISEASE
A Phase I/II protocol to evaluate the safety and efficacy of infusing genetically-engineered T-cells from HIV-negative twins to their HIV-positive twins received approval without modifications from the National Institutes of Health Recombinant DNA Advisory Committee March 6.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth